Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male

Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male

Bibliographic Details
Main Authors:	PC Das, Ramesh Kandel, Kapil Sikka, AB Dey
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-07-01
Series:	Clinical Medicine Insights: Case Reports
Online Access:	http://www.la-press.com/reversible-ototoxicity-a-rare-adverse-reaction-of-liposomal-amphoteric-article-a4297

Similar Items

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016-01-01)

Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
by: Davidson, R, et al.
Published: (1991)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014-08-01)

Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children
by: Hurşit Apa, et al.
Published: (2013-08-01)

Different liposomal amphotericin B formulations for visceral leishmaniasis–Author's reply
by: Nilima Kshirsagar
Published: (2014-08-01)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
by: Pouran Layegh, et al.
Published: (2011-01-01)

Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B
by: Betül Tavil, et al.
Published: (2008-02-01)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019-06-01)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
by: Maria Ubals, et al.
Published: (2021-09-01)

Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B
by: Embiya Dilber, et al.
Published: (2002-10-01)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis.
by: Renata A O Castro, et al.
Published: (2014-01-01)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014-08-01)

Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff
by: Eva-Maria Maintz, et al.
Published: (2014-01-01)

Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis
by: Claudia Cristina Jardim Duarte, et al.
Published: (2024-01-01)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
by: Romain Guery, et al.
Published: (2017-11-01)

<i>In Vivo</i> Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment
by: Atteneri López-Arencibia, et al.
Published: (2024-08-01)

Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
by: Muhamad Zakaria Brimo Alsaman, et al.
Published: (2024-09-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Published: (2014-04-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Published: (2014-04-01)

The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis
by: Roberto Badaro
Published: (1988-11-01)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
by: Guilherme S. Ramos, et al.
Published: (2022-05-01)

Treatment failure of pentavalent antimonial therapy for human visceral leishmaniasis: a meta-analysis
by: Caitlin M Jones, et al.
Published: (2019-12-01)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
by: Charles Abongomera, et al.
Published: (2018-05-01)

Relapse of Visceral Leishmaniasis in an HIV-Infected Patient Successfully Treated with a Combination of Miltefosine and Amphotericin B
by: Shauna McQuarrie, et al.
Published: (2015-01-01)

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area
by: Daniel Holanda Barroso, et al.
Published: (2022-09-01)

Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil
by: Philip D. Marsden
Published: (1993-12-01)

Is 24 hours infusion of Amphotericin B deoxycholate as good as liposomal Amphotericin B?
by: Swiss Medical Weekly
Published: (2002-08-01)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
by: Gert-Jan Wijnant, et al.
Published: (2018-08-01)

Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis
by: Danniele L. Vale, et al.
Published: (2023-06-01)

Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.
by: Anette Stauch, et al.
Published: (2012-01-01)

Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis
by: Si Luo, et al.
Published: (2022-11-01)

Intravenous liposomal amphotericin B efficacy and safety for cutaneous and mucosal leishmaniasis: a systematic review and meta-analysis protocol
by: Faheel Naeem, et al.
Published: (2021-06-01)

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
by: Frédéric Frézard, et al.
Published: (2022-12-01)

Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
by: Meghan R Perry, et al.
Published: (2015-03-01)

Increased thiol levels in antimony-resistant Leishmania infantum isolated from treatment-refractory visceral leishmaniasis in Brazil
by: Lucas S Magalhães, et al.

Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis
by: Zahra Alizadeh, et al.
Published: (2023-11-01)

Methods for particle size reduction of liposomal amphotericin B
by: Tuan Quang Nguyen, et al.
Published: (2018-03-01)

Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population.
by: Kishor M Wasan
Published: (2024-09-01)

Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation
by: Fauzia Jamal, et al.
Published: (2023-01-01)